Výsledky vyhledávání - "Cyrus L. Harmon"

Abstract P5-08-07: The complete estrogen receptor antagonist OP-1250 can combine with HER2 inhibition to inhibit estrogen receptor-driven cellular proliferation and shrink xenograft tumors in ER+/HER2+ breast cancer models

Autor: Alison D Parisian, Leslie Hodges-Gallagher, Richard Sun, Susanna Barratt, Gopinath S Palanisamy, Julia Lawrence, Pamela Klein, David C Myles, Cyrus L Harmon, Peter J Kushner

Publikováno v: Cancer Research. 82:P5-08

The human epidermal growth factor receptor 2 (HER2, also known as ERBB2) oncogene is overexpressed in approximately 25% of breast cancer tumors and is associated with a high rate of brain metastasis. Patients with brain metastases have a poor prognos

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0b3b17941a925fa0c99ff41f9740e18b
https://doi.org/10.1158/1538-7445.sabcs21-p5-08-07

Zobrazit plný text záznamu

Abstract 5375: Precision run-on sequencing (PRO-seq) analysis of a treatment time course in ER+ breast cancer cell lines reveals the transcriptional changes underlying response to complete estrogen receptor antagonist (CERAN) OP-1250

Autor: Alison D. Parisian, Caitlin Miller, Fabian Ortega, Leslie Hodges-Gallagher, Susanna Barratt, Joey Azofeifa, Peter J. Kushner, David Kulp, Cyrus L. Harmon

Publikováno v: Cancer Research. 82:5375-5375

OP-1250 is an orally-bioavailable complete estrogen receptor antagonist (CERAN) previously shown to shrink wild-type and Y537S mutant estrogen receptor-positive (ER+) tumors in multiple preclinical xenograft models. To better understand the effects o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e81f95f3ec55a06070792087b6e716a7
https://doi.org/10.1158/1538-7445.am2022-5375

Zobrazit plný text záznamu

Abstract 1618: OP-1250 prevents tumor spread in a model of metastatic mutant ERα+ breast cancer

Autor: Muriel Laine, Marianne E. Greene, Tiffany Leng, Sophia Li, Gopinath S. Palanisamy, Cyrus L. Harmon, Leslie Hodges-Gallagher, Peter J. Kushner, Geoffrey L. Greene

Publikováno v: Cancer Research. 82:1618-1618

Estrogen receptor positive (ER+) breast cancers represent about 70-75% of all breast cancer. In general, these cancers are effectively treated with adjuvant endocrine therapies, with or without the addition of CDK4/6 inhibitors. However, many patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e1a9eca2099e6a2dd951643bb19fb1f9
https://doi.org/10.1158/1538-7445.am2022-1618

Zobrazit plný text záznamu

Abstract LB122: The complete estrogen receptor antagonist (CERAN) OP-1250 shrinks ER+ brain metastases in an intracranial xenograft tumor model expressing mutant ESR1

Autor: Pamela M. Klein, Alison D. Parisian, Leslie Hodges-Gallagher, Richard Sun, Peter J. Kushner, David C. Myles, Cyrus L. Harmon

Publikováno v: Cancer Research. 81:LB122-LB122

Estrogen receptor-positive (ER+) breast cancer can undergo metastatic spread to the brain, which occurs in up to 15% of HER2-/ER+ metastatic breast cancer patients. Although endocrine therapy is not explicitly approved for brain metastasis and clinic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bb507c2707448e766e5366ecc3e352ae
https://doi.org/10.1158/1538-7445.am2021-lb122

Zobrazit plný text záznamu

Abstract OT-09-10: A phase I/II open-label, first-in-human, multicenter, dose escalation and dose expansion study of OP-1250 monotherapy in adult subjects with advanced and/or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer

Autor: Manish Patel, Peter J. Kushner, Cyrus L. Harmon, Pamela M. Klein, Carlos Alemany, Trinh Le, Jo Anne Zujewski, Erika Hamilton, Nan Lin

Publikováno v: Cancer Research. 81:OT-09

Background: Endocrine therapy has been the primary treatment modality for HR+, HER2- metastatic breast cancer (MBC). Endocrine agents are administered sequentially, either in combination with targeted therapy or as monotherapy. The majority of patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f944dfe2ae750ddb692d86d1df22acbc
https://doi.org/10.1158/1538-7445.sabcs20-ot-09-10

Zobrazit plný text záznamu

Abstract PS18-16: The complete estrogen receptor antagonist OP-1250 shrinks tumors in xenograft models and has favorable preclinical pharmacokinetic attributes

Autor: Pamela M. Klein, Peter J. Kushner, David C. Myles, Richard Sun, Leslie Hodges-Gallagher, Jo Anne Zujewski, Cyrus L. Harmon

Publikováno v: Cancer Research. 81:PS18-16

Antiestrogens are widely used to treat ER+, HER2- breast cancer however these may produce estrogen-like agonist effects in a cell and gene-specific manner. Furthermore, this partial agonism has been implicated in the development of tumor resistance.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d6bf30c120f0868becad3eebebeaac70
https://doi.org/10.1158/1538-7445.sabcs20-ps18-16

Zobrazit plný text záznamu

Abstract 4376: OP-1250, a complete estrogen receptor antagonist (CERAN) that shrinks estrogen receptor positive tumors and exhibits favorable pharmacokinetics

Autor: Leslie Hodges-Gallagher, Peter J. Kushner, Richard Sun, Cyrus L. Harmon, David C. Myles

Publikováno v: Cancer Research. 80:4376-4376

Fulvestrant (FASLODEX), a Complete Estrogen Receptor ANtagonist (CERAN) is recognized as the most effective endocrine therapy for estrogen receptor positive (ER+) metastatic breast cancer. Unfortunately, fulvestrant must be injected i.m. and has poor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fe2cb03886161c71a63108409578978c
https://doi.org/10.1158/1538-7445.am2020-4376

Zobrazit plný text záznamu

Abstract P5-05-02: Preclinical development of OP-1250, an oral complete estrogen receptor antagonist (CERAN) that shrinks ER-positive breast tumors in xenograft models

Autor: Leslie Hodges-Gallagher, Richard Sun, Peter J. Kushner, Cyrus L. Harmon, David C. Myles

Publikováno v: Cancer Research. 80:P5-05

Fulvestrant (FASLODEX) is the most effective endocrine therapy for estrogen receptor positive (ER+) metastatic breast cancer (MBC). Despite this superiority, fulvestrant must be delivered by intramuscular injection and its efficacy appears limited by

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3048fdf931a21a959d426e8c4f3e90da
https://doi.org/10.1158/1538-7445.sabcs19-p5-05-02

Zobrazit plný text záznamu

Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity

Autor: Leslie Hodges-Gallagher, David C. Myles, C.E. Fowler, Geoffrey L. Greene, R. Sun, Isaac N. Plant, Bradley Green, Cyrus L. Harmon, Sean W. Fanning, Peter J. Kushner

Publikováno v: Nature Communications, Vol 9, Iss 1, Pp 1-12 (2018)

Complex tissue-specific and cell-specific signaling by the estrogen receptor (ER) frequently leads to the development of resistance to endocrine therapy for breast cancer. Pure ER antagonists, which completely lack tissue-specific agonist activity, h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7f110876b6e7d20f07c16149bae58a7
https://pubmed.ncbi.nlm.nih.gov/29915250

Zobrazit plný text záznamu

A 1.1-Mb Transcript Map of the Hereditary Hemochromatosis Locus

Autor: Vincent K. Lee, Zenta Tsuchihashi, Felipa A. Mapa, Roger K. Wolff, Theodore Moore, Nicole C. Meyer, Amy Fullan, Cyrus L. Harmon, Deborah B. Loeb, David A. Ruddy, Winston Thomas, Randall C. Schatzman, Gabriel Mintier, John N. Feder, Erin E. McClelland, Leah Quintana, Alivelu Irrinki, Gregory S. Kronmal, Rodolfo Domingo

Publikováno v: Genome Research. 7:441-456

In the process of positionally cloning a candidate gene responsible for hereditary hemochromatosis (HH), we constructed a 1.1-Mb transcript map of the region of human chromosome 6p that lies 4.5 Mb telomeric to HLA-A. A combination of three gene-find

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e7a5b33f8da3c5765f413423587ca7e
https://doi.org/10.1101/gr.7.5.441

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání